test

Recent Publications

Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R.
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.
Nature. 2014 Jul 13.

Luryi AL, Yarbrough WG, Niccolai LM, Roser S, Reed SG, Nathan CA, Moore MG, Day T, Judson BL.
Public Awareness of Head and Neck Cancers: ACross-Sectional Survey.
JAMA Otolaryngol Head Neck Surg. 2014 Jun 5.

Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA.
Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging.
Int J Gynecol Cancer. 2014 Jun 12.

English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
Cancer Med. 2014 Jun 2.

Cohen EB, Jun SJ, Bears Z, Barrera FN, Alonso M, Engelman DM, Dimaio D.
Mapping the homodimer interface of an optimized, artificial, transmembrane protein activator of the human erythropoietin receptor.
PLoS One. 2014 Apr 30;9(4):e95593. 

Goodwin EC, Motamedi N, Lipovsky A, Fernández-Busnadiego R, Dimaio D.
Expression of DNAJB12 or DNAJB14 Causes Coordinate Invasion of the Nucleus by Membranes Associated with a Novel Nuclear Pore Structure.
PLoS One. 2014 Apr 14;9(4):e94322.

Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM.
Immune-based antitumor effects of BRAF Inhibitors rely on signaling by CD40L and IFN-γ.
Cancer Res. 2014 Apr 15.

Dimaio D.
Is virology dead?
MBio. 2014 Mar 25;5(2).

Buza N, Roque DM, Santin AD.
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
Arch Pathol Lab Med. 2014 Mar;138(3):343-50.

Sewell A, Brown BT, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG.
Reverse Phase Protein Array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
Clin Cancer Res. 2014 Mar 5.

Chen MM, Roman SA, Kraus DH, Sosa JA, Judson BL.
Transoral Robotic Surgery: A Population-Level Analysis.
Otolaryngol Head Neck Surg. 2014 Mar 11.

Kupfer GM.
Fanconi Anemia: A Signal Transduction and DNA Repair Pathway.
Yale J Biol Med. 2013 Dec 13;86(4):491-497.

Schwab CL, English DP, Roque DM, Santin AD.
Taxanes: their impact on gynecologic malignancy.
Anticancer Drugs. 2013 Dec 1.

Black JD, English DP, Roque DM, Santin AD.
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Womens Health (Lond Engl). 2014 Jan;10(1):45-57

Chen MM, Roman SA, Sosa JA, Judson BL.
Prognostic factors for squamous cell cancer of the parotid gland: An analysis of 2,104 patients.
Head Neck. 2013 Dec 13.

Kupfer GM.
Fanconi Anemia: A Signal Transduction and DNA Repair Pathway.
Yale J Biol Med. 2013 Dec 13;86(4):491-497.

Schwab CL, English DP, Roque DM, Santin AD.
Taxanes: their impact on gynecologic malignancy.
Anticancer Drugs. 2013 Dec 1.

English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
Gynecol Oncol. 2013 Sep 4.

Iijima N, Goodwin EC, Dimaio D, Iwasaki A.
High-risk human papillomavirus E6 inhibits monocyte differentiation to Langerhans cells.
Virology. 2013 Jul 17.

English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am J Obstet Gynecol. 2013 Jul 24.

Dimaio D, Petti LM.
The E5 proteins.
Virology. 2013 May 31.

Buza N, English DP, Santin AD, Hui P.
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
Mod Pathol. 2013 Jun 14.

Yu KP, Heston L, Park R, Ding Z, Wang'ondu R, Delecluse HJ, Miller G.
Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA.
Proc Natl Acad Sci U S A. 2013 Apr 26.

English DP, Roque DM, Santin AD.
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies.
Mol Diagn Ther. 2013 Mar 26.

Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P.
Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.
Mol Biol Cell. 2013 Feb 6.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Proc Natl Acad Sci U S A. 2013 Jan 28.

Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ, Brown JL, Ivanova AV, Issaeva N, El-Naggar AK, Yarbrough WG.
TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.
Oncogene. 2012 Oct 1.

D'Souza AD, Parish IA, Krause DS, Kaech SM, Shadel GS.
Reducing Mitochondrial ROS Improves Disease-related Pathology in a Mouse Model of Ataxia-telangiectasia.
Mol Ther. 2012 Sep 25.  

Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ, Brown JL, Ivanova AV, Issaeva N, El-Naggar AK, Yarbrough WG.
TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.
Oncogene. 2012 Oct 1.

Kim Y, Li Z, Apetri M, Luo B, Settleman JE, Anderson KS
Temporal Resolution of Autophosphorylation for Normal and Oncogenic Forms of EGFR and Differential Effects of Gefitinib.
Biochemistry. 2012 Jun 26;51(25):5212-22.

Lyidogan P, Anderson KS.
Understanding the molecular mechanism of sequence dependent Tenofovir removal by HIV-1 reverse transcriptase: Differences in primer binding site versus polypurine tract.
Antiviral Res. 2012 Aug;95(2):93-103.

McEnaney PJ, Parker CG, Zhang AX, Spiegel DA.
Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease.
ACS Chem Biol. 2012 Jul 3.

Omer B, Kadan-Lottick NS, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X.
Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults.
Br J Haematol. 2012 Jul 6.

Scheideman EH, Marlatt SA, Xie Y, Hu Y, Sutton RE, Dimaio D.
Transmember protein aptamers that inhibit CCR5 expression and HIV co-receptor function.
J Virol. 2012 Jul 18.

 

Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW.
Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study.

Br J Cancer. 2012 Jun 26;107(1):207-14.

 

Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Br J Cancer. 2012 Apr 24;106(9):1543-50.

Paglino JC, Ozduman K, van den Pol AN.
LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma.
J Virol. 2012 May 2.

Lo SM, Choi M, Liu J, Jain D, Boot RG, Kallemeijn WW, Aerts JM, Pashankar F, Kupfer GM, Mane S, Lifton RP, Mistry PK.
Phenotypic diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematological malignancy phenotype by individual genome analysis.
Blood. 2012 Apr 4.

Judson BL, Adam S, Lowlicht R, Bulsara KR.
Transcervical Double Mandibular Osteotomy Approach to the Infratemporal Fossa.
World Neurosurg. 2011 Dec 13.

Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD.
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. 
Am J Obstet Gynecol. 2011 Jul 13.

Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
Br J Cancer. 2011 Sep 13.

Li N, Matte-Martone C, Zheng H, Cui W, Venkatesan S, Tan HS, McNiff J, Demetris AJ, Roopenian D, Kaech S, Shlomchik WD.
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improves GVL and immune reconstitution.
Blood. 2011 Sep 13.

Elsahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ.
The significance of perineural invasion in early-stage cervical cancer.
Gynecol Oncol. 2011 Oct 1.

Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, Dimaio D.
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.
Virology. 2011 Nov 5.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 
Oncogene. 2011 Dec 5.

Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD.
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.
J Exp Clin Cancer Res. 2011 Nov 10;30:106.

Wollmann G, Ozduman K, van den Pol AN.
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.
Cancer J. 2012 Jan;18(1):69-81.

Elsahwi KS, Santin AD.
erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
Obstet Gynecol Int. 2011;2011:128295.

Richter, C.E., Cocco, E., Bellone, S., Silasi, D.A., Rüttinger, D., Azodi, M., Schwartz, P.E., Rutherford, T.J., Pecorelli, S., Santin, A.D.
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
(2010) American journal of obstetrics and gynecology, 203 (6), pp. 582.e1-7.